Showing results (381-390 of 397) with videos related to

Sort By:
Pageof 40
Journal of Internal Medicine|February 16, 2006
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panelP J Barter, C M Ballantyne, R Carmena, et al.
European Heart Journal|March 25, 2015
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trialsDavid Preiss, Ross T Campbell, Heather M Murray, et al.
Physical Review Letters|May 20, 2014
Double-magic nature of 132Sn and 208Pb through lifetime and cross-section measurementsJ M Allmond, A E Stuchbery, J R Beene, et al.
Lancet (London, England)|February 20, 2010
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsNaveed Sattar, David Preiss, Heather M Murray, et al.
Physical Review Letters|February 1, 2008
Extraction of weak transition strengths via the (3He, t) reaction at 420 MeVR G T Zegers, T Adachi, H Akimune, et al.
Cardiovascular Diabetology|June 6, 2019
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) FoundationJean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, et al.
European Journal of Preventive Cardiology|December 13, 2016
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering allelesJohn M Gregson, Daniel F Freitag, Praveen Surendran, et al.
Nature Communications|March 10, 2015
Genome of The Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levelsElisabeth M van Leeuwen, Lennart C Karssen, Joris Deelen, et al.
The New England Journal of Medicine|October 5, 2012
C-reactive protein, fibrinogen, and cardiovascular disease prediction, Stephen Kaptoge, Emanuele Di Angelantonio, et al.
Science Translational Medicine|June 3, 2016
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart diseaseRobert A Scott, Daniel F Freitag, Li Li, et al.
Pageof 40